ストックスクリーナーアプリを入手
4.56
3.40%
0.15
プレマーケット:
4.54
-0.02
-0.44%
前日終値:
$4.41
開ける：
$4.45
24時間の取引高:
2.26M
Relative Volume:
0.48
時価総額：
$586.73M
収益：
-
当期純損益:
$-110.78M
株価収益率:
-4.2617
EPS:
-1.07
ネットキャッシュフロー:
$-75.59M
1週間 パフォーマンス:
+10.68%
1か月 パフォーマンス:
-1.72%
6か月 パフォーマンス:
-39.60%
1年 パフォーマンス:
+70.79%
1日の値動き範囲:
$4.39
$4.615
1週間の範囲:
$4.02
$4.665
52週間の値動き範囲:
$2.689
$9.97
Humacyte Inc Stock (HUMA) Company Profile
名前
Humacyte Inc
セクター
電話
919-313-9633
住所
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
HUMA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
4.56 | 586.73M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-12-11 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-14 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-05-16 | ダウングレード | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 開始されました | Cowen | Outperform |
| 2021-09-24 | 開始されました | Oppenheimer | Outperform |
| 2021-09-22 | 開始されました | BTIG Research | Buy |
| 2021-09-16 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Humacyte Inc (HUMA) 最新ニュース
DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law - GlobeNewswire
DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - GlobeNewswire Inc.
Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital - MarketBeat
Humacyte moves to test bioengineered vessel in heart surgery - Investing.com
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting - The Manila Times
11,105 Shares in Humacyte, Inc. (NASDAQ:HUMA) Acquired by Brookstone Capital Management - Defense World
Humacyte (NASDAQ:HUMA) Stock Price Up 10%Time to Buy? - MarketBeat
Cantor Fitzgerald Boosts Earnings Estimates for Humacyte - Defense World
Humacyte FY2024 EPS Forecast Raised by Cantor Fitzgerald - MarketBeat
Humacyte (NASDAQ:HUMA) Stock Price Down 6.4%What's Next? - MarketBeat
Class Action Filed Against Humacyte, Inc. (HUMA)January 17, 2 - GuruFocus.com
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, - GlobeNewswire
HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - GlobeNewswire Inc.
HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Cantor Fitzgerald Forecasts Stronger Earnings for Humacyte - MarketBeat
Humacyte, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsHUMA - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Markets Insider
Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, - GuruFocus.com
Shareholders that lost money on Humacyte, Inc.(HUMA) should - GlobeNewswire
Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update - MarketBeat
Humacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
HUMA Lawsuit Alert! Class Action Against Humacyte, Inc. - TipRanks
The Gross Law Firm Notifies Shareholders of Humacyte, Inc.(HUMA) of a Class Action Lawsuit and an Upcoming Deadline - Marketscreener.com
Humacyte, Inc. (NASDAQ:HUMA) Receives $13.71 Consensus Target Price from Analysts - MarketBeat
Analysts Set Humacyte, Inc. (NASDAQ:HUMA) Price Target at $13.71 - Defense World
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
The Gross Law Firm Reminds Humacyte, Inc. Investors of the - GlobeNewswire
Deadline Soon: Humacyte, Inc. (HUMA) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus.com
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Humacyte, Inc. of Class Action Lawsuit and Upcoming DeadlinesHUMA - PR Newswire
HUMA DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Humacyte, Inc. Investors to Secure Counsel - The Bakersfield Californian
symbol__ Stock Quote Price and Forecast - CNN
Humacyte (NASDAQ:HUMA) Trading Down 6.4%Should You Sell? - MarketBeat
Humacyte (NASDAQ:HUMA) Given “Buy” Rating at D. Boral Capital - Defense World
Contact Levi & Korsinsky by January 17, 2025 Deadline to Join Class Action Against Humacyte, Inc.(HUMA) - Morningstar
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. LawsuitHUMA - AccessWire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securitie - GuruFocus.com
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - StreetInsider.com
Investors in Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - AccessWire
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein - GlobeNewswire
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein Liebhard - WICZ
Humacyte, Inc. Sued for Securities Law Violations – - GlobeNewswire
Humacyte's (HUMA) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Humacyte provides update on commerical launch, pricing of Symvess - TipRanks
Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma - The Manila Times
Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Humacyte, Inc. (NASDAQ:HUMA) Position Increased by Barclays PLC - Defense World
Humacyte Inc (HUMA) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):